IRLAB Therapeutics Debt 2024

IRLAB Therapeutics Aktienanalyse

What does IRLAB Therapeutics do?

IRLAB Therapeutics AB was founded in Stockholm, Sweden in 2012 and is a biopharmaceutical company specializing in the development of drugs for neurodegenerative diseases. The company has an innovative business model based on the discovery, development, and commercialization of drug candidates for various diseases. The company specializes in developing new and effective treatment options for neurodegenerative diseases. IRLAB Therapeutics AB has an extensive network of partners, including scientific institutions, universities, and clinical trial centers. With this network, the company ensures that all research and development activities are conducted using the latest scientific and technological advancements. The company operates in two segments: research and development and commercialization. In the research and development segment, the company focuses on identifying and developing drugs for neurodegenerative diseases such as Parkinson's and Alzheimer's. The company works on a pipeline of drug candidates in various stages of development, using advanced technologies such as in-silico screening and in-vivo testing to identify and develop new drug candidates. The commercialization segment of the company mainly deals with the distribution of already approved drugs. The company specializes in bringing these medications to market in its target regions. The company is particularly focused on the drugs Systebol and IRL752. Systebol is a medication for the treatment of cold-like symptoms in pregnant women and is already approved in some countries around the world. IRL752 is a substance for the treatment of psychiatric disorders and is also marketed by IRLAB Therapeutics. The main product of IRLAB Therapeutics AB is currently P21, a drug candidate for the treatment of Parkinson's disease. This drug candidate is in phase II of clinical trials and has received Orphan Drug designation from both the FDA and EMA. The company regularly reports on the progress of the clinical trials and announces ongoing news about the results. IRLAB Therapeutics AB has a clear vision and mission based on providing innovative solutions for patients with neurodegenerative diseases. The company aims to improve the lives of millions of people worldwide through the development of new and effective medical solutions. The company relies on collaboration with global and regional partners and invests in advanced technologies to establish itself as an innovative and reliable partner in the pharmaceutical industry. IRLAB Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding IRLAB Therapeutics's Debt Structure

IRLAB Therapeutics's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing IRLAB Therapeutics's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to IRLAB Therapeutics’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in IRLAB Therapeutics’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about IRLAB Therapeutics stock

What is the debt of IRLAB Therapeutics this year?

IRLAB Therapeutics has a debt level of -83.74 SEK this year.

What was the debt of IRLAB Therapeutics compared to the previous year?

The debt of IRLAB Therapeutics has increased by -66.34% compared to the previous year dropped.

What are the consequences of high debt for investors in IRLAB Therapeutics?

High debt can pose a risk for investors of IRLAB Therapeutics, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of IRLAB Therapeutics?

Low debt means that IRLAB Therapeutics has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from IRLAB Therapeutics affect the company?

An increase in debt of IRLAB Therapeutics can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of IRLAB Therapeutics affect the company?

A reduction in debt of IRLAB Therapeutics can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of IRLAB Therapeutics?

Some factors that can influence the debt of IRLAB Therapeutics include investments, acquisitions, operating costs, and revenue development.

Why are the debts of IRLAB Therapeutics so important for investors?

The debts of IRLAB Therapeutics are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can IRLAB Therapeutics take to change the debt?

To change the debt, IRLAB Therapeutics can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does IRLAB Therapeutics pay?

Over the past 12 months, IRLAB Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, IRLAB Therapeutics is expected to pay a dividend of 0 SEK.

What is the dividend yield of IRLAB Therapeutics?

The current dividend yield of IRLAB Therapeutics is .

When does IRLAB Therapeutics pay dividends?

IRLAB Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of IRLAB Therapeutics?

IRLAB Therapeutics paid dividends every year for the past 0 years.

What is the dividend of IRLAB Therapeutics?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is IRLAB Therapeutics located?

IRLAB Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von IRLAB Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of IRLAB Therapeutics from 10/6/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 10/6/2024.

When did IRLAB Therapeutics pay the last dividend?

The last dividend was paid out on 10/6/2024.

What was the dividend of IRLAB Therapeutics in the year 2023?

In the year 2023, IRLAB Therapeutics distributed 0 SEK as dividends.

In which currency does IRLAB Therapeutics pay out the dividend?

The dividends of IRLAB Therapeutics are distributed in SEK.